Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia : a PDWP/EBMT study
© 2024. The Author(s), under exclusive licence to Springer Nature Limited..
Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories. Of the 845 pediatric patients included in this study, 36% had an 11q23 abnormality, 24% had monosomy 7/del7q or monosomy 5/del5q, 24% had a complex or monosomal karyotype, and 16% had other PR cytogenetic abnormalities. In a multivariable model, 11q23 (hazard ratio [HR] = 0.66, P = 0.03) and other PR cytogenetic abnormalities (HR = 0.55, P = 0.02) were associated with significantly better overall survival when compared with monosomy 7/del7q or monosomy 5/del5q. Patients with other PR cytogenetic abnormalities had a lower risk of disease relapse after HSCT (HR = 0.49, P = 0.01) and, hence, better leukemia-free survival (HR = 0.55, P = 0.01). Therefore, we conclude that PR cytogenetic abnormalities at diagnosis predict overall survival after HSCT for AML in pediatric patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Bone marrow transplantation - 59(2024), 4 vom: 08. Apr., Seite 451-458 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41409-024-02197-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36715935X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36715935X | ||
| 003 | DE-627 | ||
| 005 | 20240408232236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-024-02197-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM36715935X | ||
| 035 | |a (NLM)38225386 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Akshay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia |b a PDWP/EBMT study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories. Of the 845 pediatric patients included in this study, 36% had an 11q23 abnormality, 24% had monosomy 7/del7q or monosomy 5/del5q, 24% had a complex or monosomal karyotype, and 16% had other PR cytogenetic abnormalities. In a multivariable model, 11q23 (hazard ratio [HR] = 0.66, P = 0.03) and other PR cytogenetic abnormalities (HR = 0.55, P = 0.02) were associated with significantly better overall survival when compared with monosomy 7/del7q or monosomy 5/del5q. Patients with other PR cytogenetic abnormalities had a lower risk of disease relapse after HSCT (HR = 0.49, P = 0.01) and, hence, better leukemia-free survival (HR = 0.55, P = 0.01). Therefore, we conclude that PR cytogenetic abnormalities at diagnosis predict overall survival after HSCT for AML in pediatric patients | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Galimard, Jacques-Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pryce, Angharad |e verfasserin |4 aut | |
| 700 | 1 | |a Bhoopalan, Senthil Velan |e verfasserin |4 aut | |
| 700 | 1 | |a Dalissier, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Dalle, Jean-Hugues |e verfasserin |4 aut | |
| 700 | 1 | |a Locatelli, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Jubert, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Mirci-Danicar, Oana |e verfasserin |4 aut | |
| 700 | 1 | |a Kitra-Roussou, Vassiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Fagioli, Franca |e verfasserin |4 aut | |
| 700 | 1 | |a Rialland, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Biffi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Wynn, Robert F |e verfasserin |4 aut | |
| 700 | 1 | |a Michel, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Tambaro, Francesco Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ahmari, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Tbakhi, Abdelghani |e verfasserin |4 aut | |
| 700 | 1 | |a Furness, Caroline L |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz, Miguel Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Sedlacek, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Bodova, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Faraci, Maura |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Kanchan |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinschmidt, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Petit, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Neel S |e verfasserin |4 aut | |
| 700 | 1 | |a Kalwak, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Corbacioglu, Selim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d 1986 |g 59(2024), 4 vom: 08. Apr., Seite 451-458 |w (DE-627)NLM012638250 |x 1476-5365 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:4 |g day:08 |g month:04 |g pages:451-458 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41409-024-02197-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 4 |b 08 |c 04 |h 451-458 | ||